Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SUVEN.NS
SellHot AirSuven Life Sciences Limited · Healthcare · India · $1.1B · Avg Vol: $3M/d
34
StockRankGet insider-trade alerts
Q
24
V
20
M
81
P/E (TTM)
—
ROE
-46.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 135.4M | 116.9M | 66.6M | 71.1M | -19.3% | 88.4M |
| EPS (INR) | -6.63 | -4.82 | -7.37 | -12.13 | — | -14.66 |
| Shares | 218.1M | 218.1M | 218.1M | 263.7M | +20.9% | 282.6M |
| Debt | 16.1M | 7.1M | 0 | 166.9M | 118.3% | 167.5M |
| Equity | 3.8B | 2.7B | 1.1B | 5.9B | 16.4% | — |
| Op CF | -1.2B | -826.2M | -1.5B | -3.0B | — | -3.0B |
| Inv CF | -2.5B | 615.9M | 1.5B | -4.6B | — | — |
| Fin CF | 4.0B | -10.5M | -7.6M | 7.6B | — | — |
Loading 1Y...
PRICE (1Y)+14.1%
SMA 50SMA 200
Close
$3.75
RSI (14)
58.5
52W High
$4.23
From 52W High
0.9%
SCORE BREAKDOWN
Quality
24
ROIC
-58.1%13.4
ROE
-46.7%19.4
GP/Assets
1.3%13.3
Op. Margin
-3776.4%4.1
FCF/Assets
-49.1%7.0
Piotroski
316.1
Int. Cover
-50.0x5.9
D/E Ratio
0.03x76.7
Current Ratio
29.15x97.9
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-25.2x25.0
P/FCF
—N/A
P/B
15.9x7.0
P/S
1146.1x2.1
Div Yield
—N/A
Momentum
81
52W High %
89%81.9
RS 6M
152%98.8
SMA 50/200
1.50x97.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+232%89.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.1B
P/E (Forward)
18.5x
Gross Margin
92.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SUVEN.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SUVEN.NS | Suven Life Sciences Limited(you) | $1.1B | 34 | Sell |
| COHANCE.NS | Cohance Lifesciences Limited | $1.8B | 37 | Hold |
| ASTRAZEN.NS | AstraZeneca Pharma India Limited | $1.8B | 30 | Sell |
| SUDEEPPHRM.NS | Sudeep Pharma Limited | $1.6B | 41 | Hold |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| ORCHPHARMA.NS | Orchid Pharma Limited | $517M | 45 | Hold |
| GUJTHEM.NS | Gujarat Themis Biosyn Limited | $622M | 52 | Hold |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| SHUKRAPHAR.NS | Shukra Pharmaceuticals Limited | $252M | 38 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%